Cost cut needed to cover Friedreich's Ataxia drug - NCPE

There would have to be "significant price reduction" in the cost of a drug to treat Friedreich's Ataxia for it to be covered by the HSE according to the National Centre for Pharmacoeconomics (NCPE).